Cognitive & Neuro Regulation
Overview
Compounds studied for neuroprotection, cognition and anxiety — the ACTH-analogue Semax, the tuftsin-analogue Selank, the nootropic Noopept and the brain-peptide cocktail Cerebrolysin, with a comparison page.
| Compound | Class | Mechanism | Primary research targets |
|---|---|---|---|
| Semax | ACTH(4–10) analogue | Neurotrophic (BDNF/NGF) induction | Cognition, neuroprotection, recovery |
| Selank | Tuftsin analogue | GABAergic modulation, enkephalinase inhibition | Anxiolysis, cognition, immunomodulation |
| Noopept | Nootropic small molecule | AMPA / BDNF-TrkB modulation | Nootropic, neuroprotection, memory |
| Cerebrolysin | Brain-peptide cocktail | Multifactorial neurotrophic support | Neuroregeneration, cognitive-decline research |
How Neurocognitive Peptides Work
These compounds modulate neurotrophic and neurotransmitter systems in different ways. Semax (an ACTH(4–10) analogue) and Noopept induce BDNF/NGF and support neuroplasticity; Selank (a tuftsin analogue) is anxiolytic through GABAergic and enkephalinase pathways; Cerebrolysin is a brain-derived peptide mixture with broad neurotrophic-factor-like activity. Together they span cognition, neuroprotection, anxiety and neurodegeneration research.
1. Neurotrophic-factor induction
Semax and Noopept upregulate BDNF/NGF and TrkB signalling, supporting neuronal survival, synaptic plasticity and long-term potentiation.
2. Neurotransmitter modulation
Semax modulates dopamine/serotonin; Selank enhances GABAergic tone (benzodiazepine-independent); Noopept facilitates AMPA-mediated transmission; Cerebrolysin mimics BDNF/GDNF/CNTF-like activity.
3. Neuroprotection & regeneration
Antioxidant and anti-apoptotic pathways, synaptogenesis and neurogenesis.
Key Properties at a Glance
| Compound | CAS number | MW (Da) | Length | Mechanism | Half-life |
|---|---|---|---|---|---|
| Semax | 80714-61-0 | ≈ 813.9 | 7 aa | Neurotrophic (BDNF/NGF) induction | ~ 30 min |
| Selank | 129954-34-3 | ≈ 751.9 | 7 aa | GABAergic modulation, enkephalinase inhibition | ~ 20 min |
| Noopept | 157115-85-0 | 342.39 | — (small molecule) | AMPA / BDNF-TrkB modulation | ~ 2–5 h |
| Cerebrolysin | N/A (mixture) | 120–10,000 | — (mixture) | Multifactorial neurotrophic support | ~ 4–6 h |
Research Evidence Summary
Representative reported findings from the literature (qualitative). See each compound page for detail.
| Compound | Key reported finding | Reference |
|---|---|---|
| Semax | Neuroprotection and functional recovery | Semax literature |
| Semax | Raises BDNF/NGF; cognitive effects | Semax literature |
| Semax | Used in ischemic-stroke recovery research | Semax clinical literature |
| Selank | Anxiolytic without sedation | Selank literature |
| Selank | Immunomodulatory (tuftsin-like) activity | Selank literature |
| Noopept | Improved memory consolidation and learning | Noopept literature |
| Noopept | Neuroprotection via AMPA modulation and BDNF induction | Noopept literature |
| Cerebrolysin | Improved outcomes in ischemic-stroke research | Cerebrolysin literature |
| Cerebrolysin | Cognitive endpoints in dementia research | Cerebrolysin literature |
| Cerebrolysin | Neurotrophic-factor-like neuroprotection | Cerebrolysin literature |
Research Dosing Overview
Typical research dose ranges from the literature (for research reference only, not human dosing guidance):
| Compound | Research dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Semax | 200–600 µg | Intranasal | 1–2×/day | 1–3 mo |
| Selank | 200–600 µg | Intranasal | 1–2×/day | 1–3 mo |
| Noopept | 10–20 mg | Oral / SL | 2–3×/day | 1–3 mo |
| Cerebrolysin | 5–20 mL | IV / IM | 3–7×/wk | 4–12 wk |
Formulation & Reconstitution
| Factor | Recommendation |
|---|---|
| Solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Reconstitution | 1–2 mL per vial (peptide-dependent) |
| Storage (lyophilized) | −20°C, desiccated, protected from light |
| Storage (reconstituted) | 2–8°C for up to 7–14 days |
| pH stability range | 5.0–7.0 |
| Oxidation-sensitive residues | Protect Met / Cys peptides from air and light; add antioxidant where relevant |
Selected References
- Blanes-Mira C, et al. Regulatory peptides in cosmetic and neuro research literature.
- Gorouhi F, Maibach HI. Role of topical and regulatory peptides. International Journal of Cosmetic Science, 2009.
- Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics, 2017.
- Khavinson VK, et al. Peptide regulation of the CNS and pineal gland (review literature).
Need research-grade peptides?
HPLC-verified, COA per batch. Tell us the quantity you need.
